Trial reportAnnals of surgical oncology2026
Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764541 (Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence-based guidelines for axillary surgical management following neoadjuvant endocrine therapy (NET) are lacking. We aimed to explore decisions to perform or omit axillary lymph node dissection (ALND) in patients with clinically node-negative breast cancer and pathologic nodal disease after NET.
methodsSemi-structured interviews were conducted with surgeons from sites that participated in PELOPS (Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study; NCT02764541), a multi-institution clinical trial that randomized patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer to NET with or without palbociclib. Interviews were recorded, professionally transcribed, and thematically analyzed.
resultsIn total, 15 surgeons from four institutions participated. Self-reported demographics included six non-Hispanic white, four Asian, two Black, one Hispanic, two with ethnicity not reported; all female gender. The median number of years in practice was 4 (IQR 3-15.5), 93.3% reported an academic practice setting, and all reported breast-only practice. Five reported receiving 6-16 new patients per month, six reported 17-25, and four reported >25. Decisions to perform or omit ALND were informed by three main themes: (1) diagnostic versus therapeutic benefit of ALND, (2) appropriateness of extrapolating data from other patient populations such as upfront surgery or neoadjuvant chemotherapy to patients treated with NET; and (3) perspective of interdisciplinary colleagues and institutional preferences.
conclusionsBased on these semi-structured interviews, future clinical trials of axillary management in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer should be designed to intentionally include patients treated with NET as either receiving upfront surgery or post-neoadjuvant therapy to provide evidence-based guidelines for management of residual nodal disease after NET.
trial registrationclinicaltrials.gov, NCT02764541.
Indexed as
Identifiers
41272386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.